160 related articles for article (PubMed ID: 34506029)
1. Improved Survival over Time After Resection of Colorectal Liver Metastases and Clinical Impact of Multigene Alteration Testing in Patients with Metastatic Colorectal Cancer.
Kawaguchi Y; Kopetz S; Panettieri E; Hwang H; Wang X; Cao HST; Tzeng CD; Chun YS; Aloia TA; Vauthey JN
J Gastrointest Surg; 2022 Mar; 26(3):583-593. PubMed ID: 34506029
[TBL] [Abstract][Full Text] [Related]
2. Mutation Status of
Kawaguchi Y; Kopetz S; Newhook TE; De Bellis M; Chun YS; Tzeng CD; Aloia TA; Vauthey JN
Clin Cancer Res; 2019 Oct; 25(19):5843-5851. PubMed ID: 31221662
[TBL] [Abstract][Full Text] [Related]
3. Alteration of FBXW7 is Associated with Worse Survival in Patients Undergoing Resection of Colorectal Liver Metastases.
Kawaguchi Y; Newhook TE; Tran Cao HS; Tzeng CD; Chun YS; Aloia TA; Dasari A; Kopetz S; Vauthey JN
J Gastrointest Surg; 2021 Jan; 25(1):186-194. PubMed ID: 33205306
[TBL] [Abstract][Full Text] [Related]
4. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.
Bond MJG; Bolhuis K; Loosveld OJL; de Groot JWB; Droogendijk H; Helgason HH; Hendriks MP; Klaase JM; Kazemier G; Liem MSL; Rijken AM; Verhoef C; de Wilt JHW; de Jong KP; Gerhards MF; van Amerongen MJ; Engelbrecht MRW; van Lienden KP; Molenaar IQ; de Valk B; Haberkorn BCM; Kerver ED; Erdkamp F; van Alphen RJ; Mathijssen-van Stein D; Komurcu A; Lopez-Yurda M; Swijnenburg RJ; Punt CJA;
Lancet Oncol; 2023 Jul; 24(7):757-771. PubMed ID: 37329889
[TBL] [Abstract][Full Text] [Related]
5. SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases.
Mizuno T; Cloyd JM; Vicente D; Omichi K; Chun YS; Kopetz SE; Maru D; Conrad C; Tzeng CD; Wei SH; Aloia TA; Vauthey JN
Eur J Surg Oncol; 2018 May; 44(5):684-692. PubMed ID: 29551247
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations.
Passot G; Chun YS; Kopetz SE; Overman MJ; Conrad C; Aloia TA; Vauthey JN
Eur J Surg Oncol; 2016 Sep; 42(9):1378-84. PubMed ID: 27358198
[TBL] [Abstract][Full Text] [Related]
7. Genomic stratification beyond Ras/B-Raf in colorectal liver metastasis patients treated with hepatic arterial infusion.
Smith JJ; Chatila WK; Sanchez-Vega F; Datta J; Connell LC; Szeglin BC; Basunia A; Boucher TM; Hauser H; Wasserman I; Wu C; Cercek A; Hechtman JF; Madden C; Jarnagin WR; Garcia-Aguilar J; D'Angelica MI; Yaeger R; Schultz N; Kemeny NE
Cancer Med; 2019 Nov; 8(15):6538-6548. PubMed ID: 31503397
[TBL] [Abstract][Full Text] [Related]
8. Genomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic Colorectal Cancer.
Kawaguchi Y; Kopetz S; Kwong L; Xiao L; Morris JS; Tran Cao HS; Tzeng CD; Chun YS; Lee JE; Vauthey JN
J Am Coll Surg; 2021 Aug; 233(2):272-284.e13. PubMed ID: 34111531
[TBL] [Abstract][Full Text] [Related]
9. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
Brouquet A; Overman MJ; Kopetz S; Maru DM; Loyer EM; Andreou A; Cooper A; Curley SA; Garrett CR; Abdalla EK; Vauthey JN
Cancer; 2011 Oct; 117(19):4484-92. PubMed ID: 21446046
[TBL] [Abstract][Full Text] [Related]
10. Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation.
Kawaguchi Y; Lillemoe HA; Panettieri E; Chun YS; Tzeng CD; Aloia TA; Kopetz S; Vauthey JN
J Am Coll Surg; 2019 Sep; 229(3):286-294.e1. PubMed ID: 31054911
[TBL] [Abstract][Full Text] [Related]
11. Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases.
Pietrantonio F; Di Bartolomeo M; Cotsoglou C; Mennitto A; Berenato R; Morano F; Coppa J; Perrone F; Iacovelli R; Milione M; Alessi A; Vaiani M; Bossi I; Ricchini F; Scotti M; Caporale M; Bajetta E; de Braud F; Mazzaferro V
Clin Colorectal Cancer; 2017 Sep; 16(3):e191-e198. PubMed ID: 27979717
[TBL] [Abstract][Full Text] [Related]
12. RAS/TP53 Co-mutation is Associated With Worse Survival After Concurrent Resection of Colorectal Liver Metastases and Extrahepatic Disease.
Lillemoe HA; Passot G; Kawaguchi Y; DeBellis M; Glehen O; Chun YS; Tzeng CD; Aloia TA; Lopez J; Vauthey JN
Ann Surg; 2022 Aug; 276(2):357-362. PubMed ID: 33351476
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
Gruenberger T; Bridgewater J; Chau I; García Alfonso P; Rivoire M; Mudan S; Lasserre S; Hermann F; Waterkamp D; Adam R
Ann Oncol; 2015 Apr; 26(4):702-708. PubMed ID: 25538173
[TBL] [Abstract][Full Text] [Related]
14. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.
Ye LC; Liu TS; Ren L; Wei Y; Zhu DX; Zai SY; Ye QH; Yu Y; Xu B; Qin XY; Xu J
J Clin Oncol; 2013 Jun; 31(16):1931-8. PubMed ID: 23569301
[TBL] [Abstract][Full Text] [Related]
15. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.
Lévi FA; Boige V; Hebbar M; Smith D; Lepère C; Focan C; Karaboué A; Guimbaud R; Carvalho C; Tumolo S; Innominato P; Ajavon Y; Truant S; Castaing D; De Baere T; Kunstlinger F; Bouchahda M; Afshar M; Rougier P; Adam R; Ducreux M;
Ann Oncol; 2016 Feb; 27(2):267-74. PubMed ID: 26578731
[TBL] [Abstract][Full Text] [Related]
16. APC and PIK3CA Mutational Cooperativity Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colorectal Liver Metastases.
Yamashita S; Chun YS; Kopetz SE; Maru D; Conrad C; Aloia TA; Vauthey JN
Ann Surg; 2020 Dec; 272(6):1080-1085. PubMed ID: 28379870
[TBL] [Abstract][Full Text] [Related]
17. Real-World Outcomes of Oxaliplatin-Based Chemotherapy on R0 Resected Colonic Liver Metastasis.
Bosma NA; Cheung WY; Thiessen M; Speers C; Renouf DJ; Tilley D; Tang PA; Ball CG; Dixon E; Lee-Ying RM
Clin Colorectal Cancer; 2021 Sep; 20(3):e201-e209. PubMed ID: 34016533
[TBL] [Abstract][Full Text] [Related]
18. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases.
Shindoh J; Loyer EM; Kopetz S; Boonsirikamchai P; Maru DM; Chun YS; Zimmitti G; Curley SA; Charnsangavej C; Aloia TA; Vauthey JN
J Clin Oncol; 2012 Dec; 30(36):4566-72. PubMed ID: 23150701
[TBL] [Abstract][Full Text] [Related]
19. TP53 Alteration and Its Effect on Pathologic Response Are Associated with Survival after Resection of Colorectal Liver Metastases.
Maki H; Haddad A; Ayabe RI; Lendoire M; Khanduri I; Maru DM; Vauthey JN
J Gastrointest Surg; 2023 Nov; 27(11):2597-2600. PubMed ID: 37553514
[TBL] [Abstract][Full Text] [Related]
20. Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer.
Masi G; Cupini S; Marcucci L; Cerri E; Loupakis F; Allegrini G; Brunetti IM; Pfanner E; Viti M; Goletti O; Filipponi F; Falcone A
Ann Surg Oncol; 2006 Jan; 13(1):58-65. PubMed ID: 16372158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
